Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells

The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resist...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Matsuda, Yasufumi, Yamauchi, Takahiro, Hosono, Naoko, Uzui, Kanako, Negoro, Eiju, Morinaga, Koji, Nishi, Rie, Yoshida, Akira, Kimura, Shinya, Maekawa, Taira, Ueda, Takanori
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4946706/
https://ncbi.nlm.nih.gov/pubmed/27166836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12965
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados